Leap Therapeutics reports Q1 2024 net loss of $13.8M; completes $40M private placement

CYPHERPUNK TECHNOLOGIES INC.

2024-Q1 EPS reported -$0.51

Net loss of $13.8M for Q1 2024 vs $41.9M Q1 2023; decrease due to $29.6M IPR&D expense from Flame merger in prior year.
Completed $40M private placement with Gilead and other investors; net proceeds $37.2M extend cash runway into Q2 2026.
Expanded Part B of DeFianCe CRC study from 130 to 180 patients; enrollment expected late Q3/Q4 2024, data mid-2025.
Part C of DisTinGuish GEJ/gastric cancer study fully enrolled (170 patients); initial data expected H2 2024 or early 2025.
Cash and equivalents $54.9M at March 31, 2024; exclusive of April 2024 private placement proceeds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2024 results: net income $13.8 million.

Period: first quarter ended March 31, 2024
Net income: $13.8 million
Result: reported results

Exact text from the filing

Net Loss was $13.8 million for the first quarter 2024, compared to $41.9 million for the same period in 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-060199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.